GTC presented abstracts at ASH 2024
GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions.
Establishing a Distinct Cytokine Signature for Multiple Myeloma
Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
Establishing Lymphoma Type-Specific Cytokine Signatures
Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)
Clonotype- naive Detection Of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
Read more Articles and News from GTC
Genomic Testing Cooperative to Exhibit and Present Research at 2026 ASCO Annual Meeting
GTC will spotlight DNA and RNA-based precision oncology testing, liquid biopsy applications and research across hematologic malignancies, breast cancer metastasis and CNS involvement CHICAGO, May
GTC and Dr. Maher Albitar Featured in Houston Business Journal
Genomic Testing Cooperative and its founder and CEO, Dr. Maher Albitar, were recently featured in the Houston Business Journal in a “Face to Face” profile highlighting
ASCO 2026 Abstracts
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile. Presenter: Adam Albitar, MD
GTC opens Houston laboratory, expanding national precision oncology network
New central U.S. location strengthens testing capacity and turnaround times while positioning GTC within the Texas Medical Center ecosystem HOUSTON — March 12, 2026 — Genomic